NAD+ IV Therapy vs Injections vs Oral Supplements: Which Delivery Method Works?

The debate around NAD+ IV therapy versus subcutaneous injections versus oral supplements comes down to a question the wellness industry rarely addresses directly: does the delivery route change the clinical outcome? The honest answer is more nuanced than most clinic websites suggest. All three routes raise circulating NAD+ levels. All three have different side effect profiles, time requirements, and cost structures. And none of them has a large Phase 3 randomized controlled trial behind it for the longevity and energy outcomes that people actually care about. Understanding where each delivery method has an advantage, and where the evidence is thin regardless of route, is the starting point for any informed conversation with a licensed provider. A useful clinical overview is available in the NIH StatPearls chapter on NAD+ biochemistry. For the specific evidence on NAD+ injections, the companion article on Lab Checklist Before Peptide Therapy covers what clinical data actually shows.

What All Three Routes Share: The NAD+ Biology

Before comparing delivery methods, the shared biology matters. NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every cell. It functions as the primary electron carrier in mitochondrial energy production, the substrate for PARP DNA repair enzymes, and the essential cofactor for sirtuin proteins that regulate gene expression and aging-related cellular stress responses.

NAD+ levels decline approximately 50% between ages 20 and 60. This decline is well-documented and has measurable consequences for cellular energy production, DNA repair capacity, and metabolic function. Raising NAD+ is a legitimate biological goal. What all three delivery methods aim to accomplish is the same thing: increase NAD+ availability in cells and tissues. Where they differ is in how directly, how rapidly, and how completely they achieve this, and at what cost in side effects, time, and money.

NAD+ IV Therapy: The Fastest Route With the Most Side Effects

NAD+ IV therapy delivers 250 to 1,000 mg of NAD+ directly into the bloodstream through a slow intravenous infusion in a clinical setting. The infusion typically runs over 2 to 4 hours. This is not an inconvenience preference. The slow rate is clinically necessary. Faster infusion rates produce higher extracellular NAD+ concentrations that trigger a pro-inflammatory response characterized by nausea, flushing, chest tightness, abdominal cramping, and a generalized sense of malaise.

What NAD+ IV therapy offers is the highest and most rapid blood NAD+ elevation of any delivery route. The 2025 retrospective tolerability pilot study published in PMC (PMC12907335) comparing IV NAD+ and IV NR in a real-world clinical population confirmed significant blood NAD+ elevation with both IV approaches. Peak concentrations achievable by IV delivery exceed what oral supplementation can produce.

The trade-offs are real. NAD+ IV therapy requires a clinical visit of 2 to 4 hours per session. It has a more pronounced side effect profile than either injections or oral supplementation. It is the most expensive delivery route. And critically, the controlled human trial evidence that higher blood NAD+ concentrations from IV delivery translate to superior clinical outcomes compared to other routes does not exist at the level required for confident conclusions.

Subcutaneous NAD+ Injections: The Middle Path

Subcutaneous NAD+ injections sit between IV therapy and oral supplementation in terms of delivery intensity. Injected under the skin rather than into a vein, they use lower doses, typically 25 to 100 mg per injection, and can be self-administered at home after appropriate training from a provider. The slower subcutaneous absorption produces a milder side effect profile than IV NAD+ therapy. Peak blood concentrations are lower than IV but higher than what most oral protocols produce per dose.

The practical advantage of subcutaneous injections is frequency without clinical burden. Where NAD+ IV therapy requires a 2 to 4 hour clinical visit that most people can commit to weekly at best, subcutaneous injections can be incorporated into a daily routine. More frequent lower-dose exposures may maintain more consistent NAD+ levels than less frequent higher-dose sessions, though this has not been formally tested in a comparative trial.

Subcutaneous NAD+ requires a physician prescription and a licensed 503A compounding pharmacy. The quality assurance considerations that apply to IV NAD+ also apply here: pharmaceutical-grade materials, sterility testing, and a Certificate of Analysis from the pharmacy are appropriate standards to confirm before beginning any injectable protocol.

Oral NMN and NR: The Most Evidence and the Lowest Barrier

Oral NAD+ precursors, primarily NMN and NR, are the delivery route with the most extensive human clinical trial evidence base. Multiple Phase 2 randomized controlled trials have tested both compounds in humans. The 2025 systematic review by Zhang et al. examined 12 NMN RCTs in 513 adults. The 2025 meta-analysis on muscle outcomes (PMC12022230) examined 10 NMN and NR RCTs. The aggregate evidence base for oral precursors is meaningfully larger than for injectable or IV routes.

The safety profile of oral NMN and NR is well-characterized. Multiple studies have confirmed safety at doses up to 1,000 mg per day with no clinically relevant adverse effects in healthy adults. This is in contrast to IV NAD+ therapy, where significant infusion-related side effects are common at standard doses.

The NMN vs NR Question

NMN and NR are both oral NAD+ precursors that enter the NAD+ biosynthesis pathway at different points. Both reliably raise blood NAD+ levels. Whether one is clinically superior for specific outcomes cannot be determined from the current evidence base. The 2026 systematic review by Poon et al. concluded that the NMN and NR human trial evidence bases are too structurally asymmetric to support reliable comparison: NR trials used doses 1.9 to 9.2 times higher than NMN on a molar basis, and the populations studied differed substantially. No head-to-head human trial comparing NMN and NR has been published as of August 2026.

One regulatory note: NMN’s status as a dietary supplement in the US became more complex after the FDA issued guidance in 2023 that NMN cannot be marketed as a dietary supplement following an IND filing. NR does not have this complication and remains available as a dietary supplement. NMN is available through some clinical programs under physician supervision. For a detailed explanation of the regulatory landscape, the article on Complete Beginner’s Guide to Peptide Therapy covers the compounding framework relevant to this space.

Which NAD+ Delivery Method Is Right for You?

There is no universally correct answer, because the right delivery method depends on the specific goal, the clinical context, and what the patient is willing to commit to in terms of time, cost, and side effect tolerance. What a licensed provider will evaluate is the specific clinical picture, not a one-size delivery preference.

For most patients exploring NAD+ as part of a longevity or health optimization protocol, starting with oral NMN or NR makes the most clinical sense: the evidence base is the largest, the safety profile is the best characterized, the cost is the lowest, and the commitment is minimal. If oral supplementation is confirmed to be appropriate after a provider evaluation, and if specific clinical indicators suggest a more intensive delivery might be warranted, upgrading to subcutaneous injections or occasional IV sessions can be considered in that order.

For context on how NAD+ relates to peptide therapy and the broader healthy aging landscape, the article on Peptides and Healthy Aging covers the complementary mechanisms. For a thorough review of what the evidence actually supports for NAD+ outcomes specifically, the article on Complete Beginner’s Guide to Peptide Therapy is essential reading before committing to any protocol. For what a first evaluation looks like, the First Consultation guide describes the process step by step.